Table 3:
Proportion of Patients with Juvenile Idiopathic Arthritis Associated Uveitis Achieving Corticosteroid-sparing Control of Inflammation
Proportion achieving corticosteroid-sparing control | ||||||
---|---|---|---|---|---|---|
Total | % | IMT alone | % | IMT in combination | % | |
Methotrexate | 33/42 | 79 | 19/25 | 76 | 14/17 | 82 |
Mycophenolate mofetil | 4/7 | 57 | 1/2 | 50 | 3/5 | 60 |
Cyclosporine | 5/6 | 83 | 1/1 | 100 | 4/5 | 80 |
Adalimumab (Humira) | 6/14 | 43 | 1/6 | 17 | 5/8 | 63 |
Etanercept (Enbrel) | 2/3 | 67 | 2/2 | 100 | 0/1 | 0 |
Infliximab (Remicade) | 10/11 | 91 | 3/3 | 100 | 7/8 | 88 |